肝细胞癌的下一代治疗:CAR-T 细胞与抗癌肽的协同作用
Next-generation therapies for hepatocellular carcinoma: CAR-T cell and anticancer peptide synergy.
肝细胞癌(HCC)是最常见的原发性肝癌,其特征为诊断偏晚、治疗效果有限以及高度免疫抑制的肿瘤微环境。
61.5分
★★★☆☆
ALL SOURCES
Next-generation therapies for hepatocellular carcinoma: CAR-T cell and anticancer peptide synergy.
肝细胞癌(HCC)是最常见的原发性肝癌,其特征为诊断偏晚、治疗效果有限以及高度免疫抑制的肿瘤微环境。
Integrated therapies for targeting the microenvironment of hepatocellular carcinoma.
肝细胞癌(HCC)微环境(MEs)由免疫和非免疫成分组成,这些成分驱动肿瘤进展和治疗耐药。
Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma.
对 195 例肝细胞癌患者肝活检标本的免疫组化显示,82.6% 为 GPC3 阳性。
Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood.
IDRA HBV-TCR T 细胞可在 Tacrolimus 和 MMF 存在下裂解全血中游离的 HBV-HCC 细胞。
共 4 条
MEMBER ACCOUNT
登录成功会直接打开下一页。